• Home
• Resources
• Blog
• Liposome Encapsulation Methods for mRNA and Gene Therapies: Mechanisms and Workflow Optimization

2026-09-11

Introduction

Messenger RNA (mRNA) has emerged as a versatile therapeutic modality for applications ranging from vaccine development and protein replacement therapy to cancer immunotherapy and gene editing. Unlike DNA-based approaches, mRNA does not require nuclear entry for translation, poses no risk of insertional mutagenesis, and can be produced rapidly by in vitro transcription. However, the clinical translation of mRNA therapeutics is severely constrained by the molecule's inherent instability, susceptibility to ribonucleases, large size, negative charge, and poor membrane permeability. These obstacles necessitate a delivery carrier that can protect the payload from extracellular degradation, facilitate cellular uptake, and enable endosomal escape. Liposomes—self-assembled phospholipid bilayer vesicles—have long been investigated as non-viral delivery vehicles for nucleic acids. Their structural versatility, biocompatibility, and ability to encapsulate hydrophilic mRNA in the aqueous core make them particularly suitable carriers. This review examines the mechanistic principles of liposome-mediated mRNA delivery, compares the principal preparation methods, and discusses critical process parameters, characterization techniques, and stability considerations that underpin scalable liposome encapsulation for gene therapy applications.

The rationale for using liposomes extends beyond simple payload protection. Because mRNA must reach the cytoplasm intact and be released from endosomal compartments before lysosomal degradation, the design of the lipid envelope directly influences transfection efficiency. The lipid composition can be tuned to incorporate cationic lipids that electrostatically condense the mRNA, helper lipids that promote bilayer fluidity, PEGylated lipids that reduce opsonization, and fusogenic or pH-sensitive lipids that trigger membrane disruption at endosomal pH. Each of these components must be balanced to maximize encapsulation efficiency while minimizing cytotoxicity and immune activation. Understanding the interplay between lipid chemistry, formulation method, and nanoparticle size is therefore essential for developing robust mRNA delivery systems.

Lipid carriers for mRNA delivery can be divided into several categories including liposomes (LPs), liposome-like nanoparticles (LLPs), solid lipid nanoparticles, and lipid nanoparticles (LNPs). While LNPs have become the dominant platform for approved mRNA vaccines, classical liposomes continue to offer certain advantages in terms of manufacturing simplicity, established regulatory history, and flexibility in cargo loading. The methods by which liposomes are prepared—such as lipid film hydration, ethanol injection, and microfluidic mixing—each impart distinct physical and chemical properties to the final formulation, affecting encapsulation efficiency, particle size distribution, and stability. This article provides a practical overview of these approaches, with a focus on optimizing the workflow for mRNA and gene therapy payloads.

Mechanisms of mRNA Encapsulation and Delivery

Liposomes protect mRNA through both physical encapsulation within the aqueous interior and electrostatic association with the bilayer. During preparation, the mRNA molecules are mixed with lipids in a solvent system that promotes spontaneous vesicle formation. In the case of cationic or ionizable liposomes, the negatively charged phosphate backbone of mRNA interacts with positively charged lipid headgroups, enabling high loading densities. Once formed, the lipid bilayer acts as a diffusion barrier that shields the mRNA from RNases in biological fluids. The size of the vesicle, typically in the range of 100–200 nm, also influences biodistribution and cellular uptake by modulating interactions with the mononuclear phagocyte system and extravasation through fenestrated endothelia.

Following administration, liposome–mRNA complexes are internalized by target cells primarily through clathrin-mediated endocytosis or macropinocytosis. Within the endocytic pathway, the maturing endosome undergoes acidification, which can be exploited to trigger cargo release. Cationic lipids with pH-responsive properties undergo a phase transition or adopt fusogenic conformations that destabilize the endosomal membrane, allowing mRNA to escape into the cytoplasm before lysosomal fusion. This endosomal escape step is a major bottleneck in nucleic acid delivery; even with optimized formulations, only a small fraction of internalized mRNA reaches the cytosol. Strategies to improve escape include incorporating dioleoylphosphatidylethanolamine (DOPE) as a helper lipid, which facilitates non-bilayer structures, and using ionizable lipids that remain uncharged at physiological pH but become protonated in the endosome, promoting membrane disruption. Teams facing similar bottlenecks often pair this approach with peg lipids when moving from discovery into validation.

The translation of delivered mRNA into functional protein requires that the released mRNA remain intact and be recognized by the host ribosome. Because exogenous mRNA can trigger innate immune sensors such as Toll-like receptors 3 and 7/8, the lipid composition must be designed to minimize inflammatory signaling. Polyethylene glycol (PEG) grafting on the liposome surface reduces recognition by immune cells and prolongs circulation time, a strategy referred to as stealth modification. The choice of liposome lipid composition is therefore a pivotal determinant of both delivery efficiency and tolerability. Tailored formulations that balance charge, stability, and fusogenic activity are essential for achieving robust protein expression in vivo.

Preparation Methods for mRNA-Loaded Liposomes

The method used to assemble mRNA-loaded liposomes profoundly affects the physicochemical properties of the final product. The historical benchmark is the lipid film hydration method, in which lipids are dissolved in an organic solvent, dried to a thin film under reduced pressure using a rotary evaporator, and then hydrated with an aqueous buffer containing the mRNA cargo. Hydration is followed by size reduction via extrusion through polycarbonate membranes with defined pore diameters (typically 100–200 nm). This method is straightforward, requires no specialized equipment, and allows fine control over lipid composition and membrane uniformity. However, the encapsulation efficiency of large mRNA molecules can be modest, and the batch size is limited by the surface area of the film.

Ethanol injection offers a scalable alternative that avoids the film drying step. In this approach, lipids dissolved in ethanol are rapidly injected into an aqueous mRNA solution under vigorous stirring. The sudden change in solvent polarity causes spontaneous formation of liposomes that entrap mRNA. Ethanol injection is compatible with continuous processing and can be adapted for aseptic manufacturing. The key parameters are the ethanol-to-aqueous volume ratio, the rate of injection, and the mixing efficiency. Because ethanol is miscible with water, the residual alcohol must be removed by dialysis or tangential flow filtration after formation. This method is suitable for both laboratory-scale studies and clinical production when optimized.

Microfluidic mixing represents the most advanced technique for producing mRNA-loaded liposomes with narrow size distribution and high batch-to-batch reproducibility. In microfluidic devices, lipid-containing ethanol stream and aqueous mRNA solution are pumped through a herringbone or staggered herringbone mixer where laminar flow enables controlled nanoprecipitation. The flow rate ratio (FRR) and total flow rate (TFR) govern the size and polydispersity of the resulting nanoparticles. This platform is particularly attractive for gene therapy applications because it can be scaled by parallelization and integrated with in-line purification and buffer exchange. Many contract development and manufacturing organizations now offer liposome preparation using microfluidic systems to meet good manufacturing practice (GMP) requirements for clinical-trial materials.

A fourth method, reverse-phase evaporation, involves forming a water-in-oil emulsion of mRNA solution in an organic phase containing lipids, followed by removal of the organic solvent under vacuum. The resulting liposomes exhibit high encapsulation efficiencies for large hydrophilic payloads, but the process is less scalable and can expose the mRNA to residual organic solvent. Therefore, for most mRNA gene therapy workflows, ethanol injection or microfluidic mixing are preferred for their scalability and compatibility with traditional lipid chemistries.

Critical Process Parameters

Regardless of the preparation method, several process parameters must be tightly controlled to achieve consistent liposome formulations with high encapsulation efficiency and stability. The flow rate ratio in microfluidic mixing determines the degree of supersaturation during nanoparticle formation. Lower FRRs (e.g., 1:1 aqueous:ethanol) tend to produce larger particles with lower mRNA loading; higher FRRs (e.g., 3:1) generate smaller, more monodisperse particles. The total flow rate also affects mixing time; faster rates enhance nanoprecipitation and reduce particle size. In ethanol injection, the alcohol concentration of the final mixture must remain below a threshold (~ performance scoped per project v/v) to avoid disrupting the bilayer or denaturing the mRNA.

Post-formation purification is essential to remove unentrapped mRNA and organic solvent residuals. Common techniques include dialysis, ultrafiltration, and size-exclusion chromatography. The choice of buffer during purification also matters; mRNA-loaded liposomes are often dialyzed against a sucrose or trehalose isotonic buffer that preserves nanoparticle integrity. Tangential flow filtration (TFF) is preferred for scale-up because it enables continuous buffer exchange and concentration without compromising liposome size. The removal of free mRNA is critical not only for dosing accuracy but also because free mRNA can induce undesired immune stimulation.

Temperature control throughout the process is another crucial factor. mRNA is thermolabile, and prolonged exposure to elevated temperatures during lipid film hydration or extrusion can degrade the payload. To maintain RNA integrity, many protocols incorporate working temperatures at or below 4°C and use RNase-inhibitory conditions such as diethylpyrocarbonate-treated water. The storage temperature after formulation also influences shelf life; liposome-encapsulated mRNA is typically stored frozen at −80°C in cryoprotectant-containing buffers to preserve both vesicle structure and mRNA integrity. Regulatory submissions require demonstrated stability data covering the intended storage period and shipping conditions.

Characterization and Encapsulation Efficiency

Rigorous characterization of mRNA-loaded liposomes is necessary for quality assurance and to establish structure-activity relationships. The primary metrics include particle size (hydrodynamic diameter measured by dynamic light scattering, DLS), polydispersity index (PDI), zeta potential, encapsulation efficiency, and RNA integrity. A monodisperse population (PDI < 0.2) is generally desired for reproducible biodistribution. Zeta potential reflects the surface charge; cationic liposomes typically exhibit positive values (≥ +20 mV), which promote cellular uptake but can also lead to rapid clearance by serum proteins. Neutral or slightly negative formulations (achieved via PEGylation) are often preferred for systemic administration.

Encapsulation efficiency is most commonly determined using a fluorescence-based RNA quantitation assay such as RiboGreen. The total RNA concentration is measured before and after the addition of a detergent that disrupts the liposomes, allowing calculation of the fraction that was protected within the bilayer. Alternatively, high-performance liquid chromatography (HPLC) with size-exclusion columns can separate free RNA from liposome-associated RNA, providing an orthogonal method. Gel retardation assays—where free mRNA migrates in an electric field while encapsulated mRNA does not—offer a simple qualitative check. For GMP release, a validated RiboGreen protocol is often combined with RNA integrity analysis by capillary electrophoresis to confirm that the mRNA has not degraded during encapsulation.

Advanced characterization techniques include cryo-transmission electron microscopy (cryo-TEM) for direct visualization of vesicle morphology and lamellarity, and small-angle X-ray scattering (SAXS) for probing the internal structure. The liposome encapsulation workflow should include a specification for minimum encapsulation efficiency — typically performance scoped per project for clinical-stage products — and a test for endotoxin levels (EU/kg body weight for injectables). Sterility testing is also required for parenteral formulations. Through liposome characterization services, developers can obtain a complete physicochemical and biological profile of their mRNA-loaded nanoparticles, facilitating process optimization and regulatory filing.

Stability Challenges and Strategies

The stability of mRNA-loaded liposomes must be maintained from manufacture through storage, transport, and administration. mRNA is inherently labile due to the 2′-OH group in its ribose backbone that makes it susceptible to hydrolysis and RNase cleavage. Even at −80°C, extended storage can lead to gradual ribose degradation. Furthermore, the liposome vesicle itself can undergo aggregation, fusion, or leakage of the encapsulated payload over time. Lyophilization (freeze-drying) is often explored to improve shelf life, but it imposes additional stresses such as ice crystallization and dehydration that can disrupt bilayer integrity and degrade mRNA.

Cryoprotectants such as sucrose, trehalose, and mannitol are routinely added to formulations before lyophilization. These sugars form a glassy matrix that stabilizes both the liposome bilayer (by replacing water molecules at the lipid headgroup interface) and the mRNA structure. Trehalose is particularly effective because it has a high glass-transition temperature and low hygroscopicity. However, the drying protocol must be optimized for each lipid composition to avoid the formation of large ice crystals that puncture vesicles. Controlled-rate freezing and primary drying at temperatures below the glass transition are essential. After reconstitution, the particle size should be comparable to the pre-lyophilized material, and the mRNA integrity must be verified by gel electrophoresis or ribogreen assay.

Beyond lyophilization, liquid formulations can be stabilized by selecting saturated or long-chain lipids that resist chemical hydrolysis and by maintaining pH near neutral. The presence of chelators such as EDTA can inhibit divalent-cation-dependent RNase activity. For clinical use, stability-indicating methods (e.g., HPLC for lipid degradation products, capillary electrophoresis for RNA fragments) must be validated as part of the release specification. Researchers working with liposome drug delivery should consult recommended storage conditions and perform forced degradation studies to identify the most vulnerable components of their formulation. Access to specialized liposome stability testing platforms can accelerate the optimization of lyoprotectant mixtures and container-closure systems.

Scaling from Laboratory to GMP

Transitioning a liposome-encapsulated mRNA product from bench-scale (milligrams) to GMP-compliant clinical supply (grams to kilograms) requires careful re-evaluation of each unit operation. The formulation method, raw materials, and equipment must be qualified to ensure that critical quality attributes are maintained. For ethanol injection and microfluidic mixing, scaling is often achieved by increasing the number of parallel channels or the diameter of the mixer. However, parameters such as mixing efficiency, shear stress, and residence time can change with scale, requiring re-optimization of flow rate and FRR. Tangential flow filtration for purification scales linearly with membrane area, making it suitable for continuous processing.

Lipid raw materials—especially synthetic phospholipids and PEG-lipids—must be sourced from qualified suppliers with appropriate regulatory documentation. Each lipid lot should be tested for identity, purity, and absence of peroxides before use. The mRNA drug substance, typically provided in a frozen aqueous solution, must be thawed and formulated under RNase-free conditions. In-process controls during GMP production include measurement of the intermediate particle size, encapsulation efficiency by RiboGreen, and osmolarity. The final bulk product is filtered through a 0.2 µm sterile filter and filled into vials under aseptic conditions. Release testing includes the full battery of characterization methods plus bioburden, endotoxin, and general safety tests.

Contract development organizations now provide comprehensive liposome services that guide sponsors through the entire scale-up pathway, from preformulation studies to GMP batch release and stability programs. These services often include feasibility runs where multiple lipid compositions and process conditions are screened at small scale, followed by a technology transfer to a GMP facility. By leveraging established manufacturing platforms, gene therapy developers can reduce the risk of process failure and accelerate the path to clinical trials. The choice of partner should be based on experience with nucleic acid payloads, quality systems, and regulatory track record.

Quality Control and Regulatory Considerations

Quality control (QC) for liposome-encapsulated mRNA products encompasses identity, purity, potency, safety, and stability. The identity test typically confirms the presence of the correct mRNA sequence by RT-PCR or sequencing. Purity is assessed by measuring free mRNA, lipid degradation products (e.g., lysophospholipids), organic solvent residuals, and endotoxin. Potency is determined by an in vitro transfection assay in which the liposome-mRNA formulation is applied to a cell line and the expression of the encoded protein is measured by ELISA or flow cytometry. This functional test must be validated for accuracy, precision, and linearity.

Regulatory expectations follow ICH guidelines for pharmaceutical development. QbD (Quality by Design) principles are encouraged, meaning that the formulation and process parameters should be linked to clinical performance through design of experiments. For gene therapy products, additional guidance may apply regarding vector characterization, biodistribution studies, and long-term follow-up. Sterility assurance is paramount; all aseptic filling processes must be validated with media fills. The container closure system must prevent leakage and protect from light and moisture. Stability studies should be conducted under ICH storage conditions (e.g., 25°C/ performance scoped per project RH accelerated, 5°C long-term) with at least three time points.

Documentation requirements include a master batch record, deviations, and a certificate of analysis for each batch. A well-designed QC program not only satisfies regulatory requirements but also builds process understanding, enabling continuous improvement. As the field of mRNA gene therapy expands, standardized analytical methods for liposome characterization—such as those offered through dedicated liposome characterization workstreams—will facilitate comparability studies and support regulatory filings across different sponsors.

Explore our comprehensive liposome for mRNA encapsulation, including formulation optimization, process scale-up, and GMP manufacturing. Our scientific team can help you design the ideal liposome formulations to meet your gene therapy targets.

Frequently Asked Questions